Ginkgo Bioworks Holdings Reports Q2 2025 Earnings: Revenue Down 12%, Net Loss Narrows by 72%

Ginkgo Bioworks Holdings reported Q2 2025 revenue of $49.6m, a 12% decrease from Q2 2024, and a net loss of $60.3m, a 72% narrowing from Q2 2024. The company's shares are down 13% from a week ago. Despite this, revenue exceeded analyst estimates by 19% and earnings per share surpassed analyst estimates by 30%.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) reported its financial results for the second quarter (Q2) of 2025, showing a 12% decrease in revenue to $49.6 million compared to Q2 2024, and a net loss of $60.3 million, which was a 72% improvement from the same period last year. Despite the overall loss, the company's shares declined by 13% from a week ago, but revenue exceeded analyst estimates by 19% and earnings per share surpassed analyst estimates by 30%.

Revenue and Revenue Growth

The company's total revenue for Q2 2025 was $49.6 million, down from $56 million in the same period last year. Cell engineering revenue increased to $39 million, up 8% year-over-year, primarily driven by growth with biopharma and government customers. Biosecurity revenue decreased to $10 million, down from $20 million in the prior year period, reflecting challenges in securing international contracts [1].

Operating Expenses and Cash Position

Adjusted EBITDA for Q2 2025 was negative $28 million, up from negative $99 million in the same period last year, driven by a decrease in operating expenses. The company's cash position remained strong, with $474 million in cash and cash equivalents as of June 30, 2025, and no bank debt [1].

Outlook for 2025

Ginkgo Bioworks expects total revenue of $167 million to $187 million in 2025, with cell engineering revenue between $117 million to $137 million and biosecurity revenue at least $40 million [1]. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through strategic cost management and revenue growth, particularly from its tools and automation offerings [2].

Key Highlights from the Earnings Call

During the earnings call, Jason Kelly, CEO, highlighted the importance of automation in Ginkgo's future business and the potential for automation to become a majority of the company's business. The company is also open to demonstrating its capabilities on partners' RAC hardware and installing RAC systems at customers' sites [1].

Conclusion

Ginkgo Bioworks reported mixed financial results for Q2 2025, with a decrease in revenue and a net loss, but strong improvements in adjusted EBITDA and a robust cash position. The company's outlook for 2025 remains positive, with expectations for revenue growth and a focus on achieving adjusted EBITDA breakeven by the end of the year.

References

[1] https://finance.yahoo.com/news/ginkgo-bioworks-holdings-inc-dna-074635970.html
[2] https://www.biospace.com/press-releases/ginkgo-bioworks-reports-second-quarter-2025-financial-results